Barclays Maintains DaVita(DVA.US) With Hold Rating, Maintains Target Price $150
Barclays analyst Andrew Mok CFA maintains $DaVita(DVA.US)$ with a hold rating, and maintains the target price at $150.According to TipRanks data, the analyst has a success rate of 46.1% and a total av
Novo Weight Loss Therapy Cuts Mortality Risk in Kidney Disease
A Look At The Intrinsic Value Of DaVita Inc. (NYSE:DVA)
Here's Why You Should Add Ecolab (ECL) to Your Portfolio Now
Why DaVita HealthCare (DVA) Is a Top Momentum Stock for the Long-Term
Three Reasons to Retain Merit Medical (MMSI) Stock for Now
Merit Medical's (MMSI) Latest Launch to Boost Patient Care
Reasons to Add HealthEquity (HQY) Stock to Your Portfolio
DaVita (DVA) Gains 34.5% YTD: What's Driving the Stock?
Three Reasons to Retain Inspire Medical (INSP) Stock for Now
McKesson (MCK) Hits 52-Week High: What's Driving the Stock?
Masimo's (MASI) New Offering to Serve Personalized Audio Market
Boston Scientific (BSX) Reaches 52-Week High: What's Aiding It?
Fresenius SE's Future With Dialysis Company Unclear, Investors Seek Answers
Investors demanded more clarity from German healthcare group Fresenius SE regarding its intentions to relinquish strategic control over dialysis group Fresenius Medical Care AG (NYSE:FMS). The investo
Three Reasons to Retain AMN Healthcare (AMN) Stock for Now
Merit Medical (MMSI) to Expand Product Suite Via New Launch
DaVita Is Maintained at Hold by Truist Securities
DaVita Is Maintained at Hold by Truist Securities
Why This 1 Growth Stock Could Be a Great Addition to Your Portfolio
Denver, CO-headquartered DaVita Inc. is a leading provider of dialysis services in the U.S. to patients suffering from chronic kidney failure, also known as end-stage renal disease (ESRD).
DaVita Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 05/15/2024 9.38% Truist Securities $135 → $150 Maintains Hold 05/06/2024 9.38% Barclays $133 → $150 Mainta
Truist Financial Keeps Their Hold Rating on DaVita (DVA)